The 3-year overall survival rate for non-metastatic Ewing sarcoma patients treated with the TEMIRI protocol was 85% with manageable toxicity.
Does temozolomide and irinotecan improve survival in adult patients with relapsed/refractory Ewing sarcoma?
The TEMIRI regimen is a feasible and effective treatment option for adult patients with relapsed or refractory Ewing sarcoma, achieving a median PFS of 7 months.
Absolute Event Rate: 0% vs 0%
patients, with a median dose of 50.4Gy.The local control rate at 3 years was 70 %.The 3 year overall survival (OS) and disease-free survival (DFS) of the non-metastatic patients were 85 % and 78%, respectively.Acute toxicities were predominantly Grade I-II, while Grade III-IV toxicities were observed in 10 % of patients.Conclusions: Radiotherapy in Ewings sarcoma remains an important modality for achieving local control, particularly in unresectable tumors or positive-margin disease.Acceptable toxicity and favorable survival outcomes highlight the importance of multidisciplinary management.
Zivkovic et al. (Sun,) reported a other. The 3-year overall survival rate for non-metastatic Ewing sarcoma patients treated with the TEMIRI protocol was 85% with manageable toxicity.